ArticleBioconjugate chemistry2009
Tamoxifen-poly(ethylene glycol)-thiol gold nanoparticle conjugates: enhanced potency and selective delivery for breast cancer treatment.
Article in Bioconjugate chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 267 citations in OpenAlex.
- Cerium oxide nanoparticles: antioxidant properties in silicosis treatment and biomedical application prospects-a dialectical consideration.Drug delivery · 2026Review
- BMV and CCMV-Based Viral Nanoparticles for Delivery ofACS omega · 2026Article
- Novel Pyrazole-3-Cyano-2-Pyridinone Hybrids as Multitarget Anti-Inflammatory Agents: Synthesis, Computational Modeling, and Biological Evaluation.Drug design, development and therapy · 2026Article
- MicroRNA-targeted nanoparticle delivery systems for cancer therapy: current status and future prospects.Nanomedicine (London, England) · 2025Review
- Biogenic nanoparticles: pioneering a new era in breast cancer therapeutics-a comprehensive review.Discover nano · 2024Review
- Potential of covalently linked tamoxifen hybrids for cancer treatment: recent update.RSC medicinal chemistry · 2024Review
- Tackling breast cancer with gold nanoparticles: twinning synthesis and particle engineering with efficacy.Nanoscale advances · 2024Review
- Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy.Asian journal of pharmaceutical sciences · 2024Review
- Doxorubicin-Based Ionic Nanomedicines for Combined Chemo-Phototherapy of Cancer.ACS applied nano materials · 2024Article
- Recent nanotheranostic approaches in cancer research.Clinical and experimental medicine · 2024Review
- Metal-based nanoparticle in cancer treatment: lessons learned and challenges.Frontiers in bioengineering and biotechnology · 2024Review
- Real-Time Monitoring and Control of Nanoparticle Formation.Journal of the American Chemical Society · 2023Article
- Phytoestrogen-derived multifunctional ligands for targeted therapy of breast cancer.Asian journal of pharmaceutical sciences · 2023Article
- Efficacy of Green Synthesized Nanoparticles in Photodynamic Therapy: A Therapeutic Approach.International journal of molecular sciences · 2023Review
- Nanomedicine in therapeutic warfront against estrogen receptor-positive breast cancer.Drug delivery and translational research · 2023Review
- A review of FDA approved drugs and their formulations for the treatment of breast cancer.Frontiers in pharmacology · 2023Review
- Phytochemical-conjugated bio-safe gold nanoparticles in breast cancer: a comprehensive update.Breast cancer (Tokyo, Japan) · 2022Review
- Monodisperse Gold Nanoparticles: A Review on Synthesis and Their Application in Modern Medicine.International journal of molecular sciences · 2022Review
- Treasure on the Earth-Gold Nanoparticles and Their Biomedical Applications.Materials (Basel, Switzerland) · 2022Review
- Targeted Delivery Methods for Anticancer Drugs.Cancers · 2022Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
The breast cancer treatment drug tamoxifen has been widely administered for more than three decades. This small molecule competes with 17beta-estradiol for binding to estrogen receptor, a hormone receptor upregulated in a majority of breast cancers, subsequently initiating programmed cell death. We have synthesized a thiol-PEGylated tamoxifen derivative that can be used to selectively target and deliver plasmonic gold nanoparticles to estrogen receptor positive breast cancer cells with up to 2.7-fold enhanced drug potency in vitro. Optical microscopy/spectroscopy, time-dependent dose-response data, and estrogen competition studies indicate that augmented activity is due to increased rates of intracellular tamoxifen transport by nanoparticle endocytosis, rather than by passive diffusion of the free drug. Both ligand- and receptor-dependent intracellular delivery of gold nanoparticles suggest that plasma membrane localized estrogen receptor alpha may facilitate selective uptake and retention of this and other therapeutic nanoparticle conjugates. Combined targeting selectivity and enhanced potency provides opportunities for both multimodal endocrine treatment strategies and adjunctive laser photothermal therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.